Safety and Efficacy of a Proprietary Platform Technology-Based Curcumin on Arthritis, Joint Pain, and Mobility
Keywords:Rheumatoid arthritis, joint pain, curcumin, double-blind clinical trial, bioavailability, efficacy safety
AbstractRheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that affects the joints, skin, eyes, heart, kidneys, and lungs. Since there is no complete cure for RA, the treatment goals are to alleviate discomfort and prevent or decrease the progression of the disease. Curcumin, the active component of the common spice turmeric, has a wide range of biological activities by modulating several transcription factors and signalling pathways. However, limiting factors of regular curcumin include solubility, absorption in the gut, metabolism, and systemic elimination. BioSOLVE Curcumin® is an improved formulation developed to overcome these problems. In the current study, BioSOLVE Curcumin® was investigated for safety and efficacy in RA complications. For a period of 12 weeks, 24 individuals with RA were given 250 mg of BioSOLVE Curcumin® or as placebo capsules twice a day. ACR20 (American College of Rheumatology-20), VAS (Visual Analogue Scale), and WOMAC (Western Ontario and McMaster) scales were used to analyse the comparative efficacy of the investigational product, BioSOLVE Curcumin®, in active RA. In healthy middle-aged and older individuals with RA, BioSOLVE Curcumin was found to be a safe and effective supplementation for lowering RA symptoms, including pain and stiffness, as well as improving physical function.